IRB Company, Inc. (IRBCo), an independent review board that protects the rights and well-being of research volunteers participating in human research, announces its Full Accreditation status by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
Accreditation by AAHRPP offers assurances to research participants, researchers, sponsors, government regulators and the general public that IRBCo is focused on excellence in its human research protection programs.
"IRBCo has dedicated itself to remaining at the forefront of human research protections, and this voluntary process to earn accreditation required us to examine and review our operations and functions so that we remain a leading provider of central independent review board services," said Anil Sharma, MD, MBA, CIP, the Medical Director and Chief Executive Officer of IRBCo. "Accreditation validates our comprehensive program, which integrates ethical reviews, state-of-the-art technology and staff development."
As an independent, non-profit accrediting body, AAHRPP uses a voluntary, peer-driven educational model to ensure that human research protection programs meet rigorous standards for quality and protection. To earn accreditation, organizations must provide evidence, through policies, procedures and practices, of their commitment to scientifically and ethically sound research and to continuous improvement.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.